Comment Period Extended to 3/23/2015 for Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials
Text Size
25 studies found for:    Open Studies | "Granulomatous Disease, Chronic"

Modify this search | How to Use Search Results

Show Display Options
Rank Status Study
1 Recruiting Patients Treated for Chronic Granulomatous Disease (CGD) Since 1995
Condition: Granulomatous Disease, Chronic
Intervention:
2 Not yet recruiting Study of Gene Therapy Using a Lentiviral Vector to Treat X-linked Chronic Granulomatous Disease
Condition: Granulomatous Disease, Chronic, X-linked
Intervention: Biological: Lentiviral G1XCGD Gene Therapy
3 Recruiting Matched Unrelated or Non-Genotype Identical Related Donor Transplantation For Chronic Granulomatous Disease
Condition: Chronic Granulomatous Disease
Interventions: Drug: Busulfan;   Biological: Alemtuzumab;   Drug: Cyclophosphamide;   Drug: Fludarabine;   Drug: Cyclosporine;   Procedure: Stem Cell Infusion
4 Not yet recruiting Chronic Granulomatous Disease Study in China
Condition: Granulomatous Disease, Chronic
Intervention:
5 Not yet recruiting Analysis of Patients Treated for Chronic Granulomatous Disease Since January 1, 1995
Condition: Chronic Granulomatous Disease
Intervention:
6 Recruiting Haploidentical Transplant for People With Chronic Granulomatous Disease Using Post Transplant Cyclophosphamide
Condition: Chronic Granulomatous Disease
Interventions: Drug: Pre-Transplant Conditioning Medications;   Other: Haploidentical Cellular Infusion;   Drug: Post-Trasnplant Medications;   Radiation: Total Body Irradiation
7 Recruiting Radiofrequency Ablation for Liver Abscesses From Chronic Granulomatous Disease
Condition: Chronic Granulomatous Disease (CGD)
Intervention: Device: Cool-tip RF Ablation System
8 Recruiting Gene Therapy for X-linked Chronic Granulomatous Disease (X-CGD)
Condition: X-Linked Chronic Granulomatous Disease
Intervention: Genetic: X vivo gene therapy
9 Recruiting Targeted Busulfan, Fludarabine Conditioning Regimen for Hematopoietic Stem Cell Transplantation in Chronic Granulomatous Disease(CGD)
Condition: Chronic Granulomatous Disease
Intervention: Drug: Busulfan
10 Recruiting Collection of Lung Fluid and Tissue Samples for Research
Conditions: Mycobacterium Infections, Atypical;   Granulomatous Disease, Chronic;   Job's Syndrome;   Influenza, Human
Intervention:
11 Recruiting Non-Invasive Assessment of Atherosclerosis in Patients With CGD and Other Disorders of the Immune System
Conditions: Chronic Granulomatous Disease (CGD);   Atherosclerosis;   Immune Deficiencies;   Inflammatory Bowel Disease
Intervention:
12 Recruiting Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)
Conditions: Hemophagocytic Lymphohistiocytosis;   Chronic Active Epstein-Barr Virus Infection;   Chronic Granulomatous Disease;   HIGM-1;   Leukocyte Adhesion Deficiency;   IPEX
Intervention: Biological: Hematopoietic Stem Cell Transplant
13 Recruiting Use of G-CSF to Obtain Blood Cell Precursors
Conditions: Chronic Granulomatous Disease;   Healthy;   Immunologic Disease;   Leukocyte Adhesion Deficiency Syndrome;   Severe Combined Immunodeficiency
Intervention:
14 Recruiting Gene Therapy for X-CGD
Condition: X-linked Chronic Granulomatous Disease
Intervention: Genetic: ex-vivo gene-therapy
15 Recruiting Abatacept Reduced Intensity for Non-Malignant Diseases
Conditions: Hurler Syndrome;   Fanconi Anemia;   Glanzmann Thrombasthenia;   Wiskott-Aldrich Syndrome;   Chronic Granulomatous Disease;   Severe Congenital Neutropenia;   Leukocyte Adhesion Deficiency;   Shwachman Diamond Syndrome;   Diamond Blackfan Anemia;   Dyskeratosis Congenita;   Chediak Higashi Syndrome;   Severe Aplastic Anemia;   Thalassemia;   Hemophagocytic Lymphohistiocytosis
Interventions: Drug: 4 doses of abatacept;   Drug: 6 doses of abatacept
16 Recruiting Detection and Characterization of Infections and Infection Susceptibility
Conditions: Immune Disorders;   Chronic Granulomatous Disease;   Genetic Immunological Deficiencies;   Hyperimmunoglobulin-E Recurrent Infection Syndrome;   Recurrent Infections;   Unknown Immune Deficiency;   GATA2 Deficiency (MonoMAC),;   Nontuberculous Mycobacterial Infections;   Hyper IgE (Job s) Syndrome;   Leukocyte Adhesion Deficiency;   Susceptibility to Disseminated Infections;   Primary Immune Deficiency Disease (PIDD)
Intervention:
17 Recruiting Immune Disorder HSCT Protocol
Conditions: Immune Deficiency Disorders:;   Severe Combined Immunodeficiency;   Chronic Granulomatous Disease;   X-linked Agammaglobulinemia;   Wiskott-Aldrich Syndrome;   Hyper-IgM;   DiGeorge Syndrome;   Chediak-Higashi Syndrome;   Common Variable Immune Deficiency;   Immune Dysregulatory Disorder:;   Hemophagocytic Lymphohistiocytosis;   IPEX;   Autoimmune Lymphoproliferative Syndrome;   X-linked Lymphoproliferative Syndrome
Intervention: Drug: Transplant preparative regimen of alemtuzumab, fludarabine, thiotepa, and melphalan
18 Recruiting Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
Conditions: SCID;   Omenn's Syndrome;   Reticular Dysgenesis;   Wiskott-Aldrich Syndrome;   Bare Lymphocyte Syndrome;   Common Variable Immunodeficiency;   Chronic Granulomatous Disease;   CD40 Ligand Deficiency;   Hyper IgM Syndrome;   X-linked Lymphoproliferative Disease;   Hemophagocytic Lymphohistiocytosis;   Griscelli Syndrome;   Chediak-Higashi Syndrome;   Langerhan's Cell Histiocytosis
Interventions: Drug: Alemtuzumab 0.3 mg;   Drug: Cyclophosphamide;   Drug: Busulfan;   Biological: Stem Cell Transplantation;   Drug: Fludarabine phosphate 40 mg;   Drug: Melphalan;   Drug: Alemtuzumab 0.2 mg;   Drug: Fludarabine  phosphate 30 mg;   Drug: MESNA
19 Recruiting Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
Conditions: Severe Combined Immunodeficiency (SCID);   Immunodeficiency With Predominant T-cell Defect, Unspecified;   Severe Chronic Neutropenia;   Chronic Granulomatous Disease (CGD);   Hyper IgE Syndromes;   Hyper IgM Deficiencies;   Wiskott-Aldrich Syndrome;   Mendelian Susceptibility to Mycobacterial Disease;   Common Variable Immune Deficiency (CVID)
Intervention: Biological: CD3/CD19 negative allogeneic hematopoietic stem cells
20 Recruiting Evaluating the Transition From Pediatric to Adult Care Among Adolescents With Chronic Granulomatous Disease
Condition: CGD
Intervention:
To Top

   Previous Page Studies Shown (1-20) Next Page (21-25) Show next page of results    Last Page
† Indicates status has not been verified in more than two years